In the future, if HER2-targeted therapy enters clinical practice in bladder cancer, routine IHC assessment of HER2 would acquire diagnostic significance as well (similar to testing for PD-L1 or FGFR mutations in certain patients). Here, ERBB2 is linked to urinary bladder cancer.